Start with its own history
At 17.95×, 000513.SZ is 3.7% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

Current valuation, historical context, and peer comparisons.
Current P/E ratio
17.95×
3.7% belowthe 10-year annual average
Price and EPS in quote currency. Calculation details
Investors are paying 17.95 for every 1 of reported earnings per share.
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2025 | 15.18× | -10.5% |
| Dec 31, 2024 | 16.96× | +1.8% |
| Dec 31, 2023 | 16.67× | +4.7% |
| Dec 31, 2022 | 15.92× | -24.8% |
| Dec 31, 2021 | 21.16× | -4.4% |
| Dec 31, 2020 | 22.13× | -8.7% |
| Dec 31, 2019 | 24.24× | +53.7% |
| Dec 31, 2018 | 15.78× | +91.8% |
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2017 | 8.23× | -72.7% |
| Dec 31, 2016 | 30.09× | -14.8% |
| Dec 31, 2015 | 35.32× | +24.5% |
| Dec 31, 2014 | 28.38× | +21.5% |
| Dec 31, 2013 | 23.36× | -0.3% |
| Dec 31, 2012 | 23.42× | +40.7% |
| Dec 31, 2011 | 16.65× | -45.7% |
| Dec 31, 2010 | 30.68× | +24.0% |
| Dec 31, 2009 | 24.75× | -75.8% |
| Dec 31, 2008 | 102.35× | +294.2% |
| Dec 31, 2007 | 25.97× | +158.4% |
| Dec 31, 2006 | 10.05× | -17.4% |
| Dec 31, 2005 | 12.17× | -25.3% |
| Dec 31, 2004 | 16.29× | -0.6% |
| Dec 31, 2003 | 16.38× | -47.7% |
| Dec 31, 2002 | 31.33× | -26.0% |
| Dec 31, 2001 | 42.35× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
000513.SZ This stockLivzon Pharmaceutical Group Inc. | 17.95× |
600380.SSJoincare Pharmaceutical Group Industry Co.,Ltd. | 16.87× |
000999.SZChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | 13.09× |
600664.SSHarbin Pharmaceutical Group Co., Ltd. | 22.81× |
002294.SZShenzhen Salubris Pharmaceuticals Co., Ltd. | 47.77× |
600196.SSShanghai Fosun Pharmaceutical (Group) Co., Ltd. | 17.59× |
002422.SZSichuan Kelun Pharmaceutical Co., Ltd. Class A | 35.58× |
600276.SSJiangsu Hengrui Medicine Co., Ltd. | 35.96× |
000538.SZYunnan Baiyao Group Co.,Ltd | 18.80× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
At 17.95×, 000513.SZ is 3.7% below its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
The median of the 8 positive peer ratios above is 20.81×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore Wisesheets=WISE("000513.SZ", "PE Ratio", "LQ")Share price 31.29 ÷ EPS 1.7434 = 17.95×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 10, 2026; this is not a real-time trading quote.
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
The essentials behind the numbers.